The Size of the Asia Pacific Plasma Fractionation Market is valued at USD 4.46 billion in 2019 and is projected to be growing at a CAGR of 9.6%, to touch USD 6.7 billion by 2024 during the forecast period 2019-2024.
Plasma, which constitutes about 55% of blood by volume consists of several different proteins numbering into the thousands, and other substances like minerals, hormones, etc. There are many therapeutic uses for the proteins present in plasma. For example, Albumin is commonly used to rejuvenate and maintain blood volume after traumatic injury, during surgery and during the exchange of plasma.
Plasma Fractionation consists of the fractionation of blood into its constituent parts of red cells, white cells, and platelets, which are suspended in plasma. The plasma is studied for deficiencies relating to blood disorders and replaced or supplemented with a cure.
The growth of the Asia Pacific Plasma Fractionation Market is mainly driven by factors such as the growing use of immunoglobulins, which are basically antibodies, the increasing prevalence of immune and bleeding disorders, growing occurrence of Alpha-1 Antitrypsin deficiency and the aging population which is prone to blood-related ailments. However, adversarial reactions related to the procedure of plasma fractionation and transfer, high costs of plasma products and unfavorable reimbursement policies are the main constraints of market growth.
This research report on Asia Pacific Plasma Fractionation Market has been segmented and sub-segmented into the following categories and evaluated market size and forecast for each segment until 2024.
Some of the Promising Companies leading the Asia Pacific Plasma Fractionation Market Profiled in the Report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France)
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Fractionation Process
5.1.3 Immunoglobulin
5.1.4 Coagulation Factor Concentrates
5.1.5 Albumin
5.1.6 Protease Inhibitors
5.1.7 Y-o-Y Growth Analysis, By Product
5.1.8 Market Attractiveness Analysis, By Product
5.1.9 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Neurology
5.2.3 Immunology
5.2.4 Hematology
5.2.5 Critical Care
5.2.6 Pulmonology
5.2.7 Hemato-Oncology
5.2.8 Rheumatology
5.2.9 Other Application
5.2.10 Y-o-Y Growth Analysis, By Application
5.2.11 Market Attractiveness Analysis, By Application
5.2.12 Market Share Analysis, By Application
5.3 End User
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Clinical Laboratories
5.4.4 Academic Institutes
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxalta Incorporated
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 CSL Ltd.
8.3 Grifols S.A
8.4 Octapharma AG
8.5 Kedrion S.p.A
8.6 Bio Products Laboratory
8.7 Sanquin
8.8 China Biologic Products, Inc.
8.9 Biotest AG
8.10 Laboratoire Français du Fractionnement et des Biotechnologies
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
